Allergopharma Award


MariaPinoYanes thumbnail2 EAACI Allergopharma Award 2022

To be presented at EAACI Hybrid Congress 2022, on 1 July 2022 to the winner, 
Janice Layhadi – PhD

The awarded research project: “Precision Immunology And Biomarkers Of Allergy And Immunotherapy” and her research interest primarily involves identifying underpinning molecular mechanisms in innate lymphoid cells associated with immune tolerance. She has defined a new subset of innate lymphoid cells, IL-10+ ILC2, that are induced following allergen immunotherapy and correlate with clinical efficacy. Dr Layhadi leads the single-cell multi-omic research and has identified novel biomarkers for AIT response. Her research has resulted in several peer-reviewed publications in high-impact journals within the field of Allergy. 

MariaPinoYanes thumbnail2 EAACI Allergopharma Award 2021

Presented at EAACI Hybrid Congress 2021, on 10 July 2021 to the winner, 
Maria Pino-Yanes – PhD

The awarded research project "Uncovering the genetic component of asthma and asthma-related phenotypes in populations with African admixture” recognizes the work performed to disentangle the role of genetic ancestry in asthma and lung function, the application of admixture mapping approaches in asthma-related traits, and the study of the genetic factors involved in asthma exacerbations in Latino and African American populations.


20200821 Allergopharma award winner 2020 Rodrigo Jimenez Saiz picture EAACI Allergopharma Award 2020

Presented at EAACI Digital Congress 2020, on 6 June 2020 to the winner, Rodrigo Jiménez-Saiz – PhD

The awarded research project: “The IgE Memory Reservoir In Food Allergy” changed the paradigm on the maintenance of persistent food allergies. Using preclinical models of skin and oral sensitization, it was shown that the IgE plasma cell compartment is transient; and that sustained IgE responses are due to long-lived IgG1+ memory B cells. Upon allergen exposure, these cells regenerate the IgE compartment via CD4 T cell and IL-4 help. In addition, it was demonstrated the extreme rarity of IgE+ memory B cells in human allergic patients. Altogether, these findings strengthened the concept that the reservoir of IgE-secreting cells resides in memory B cells of a non-IgE isotype and identified new therapeutic targets for food allergy.


2019 Allergopharma winner Flore Amat EAACI Allergopharma Award 2019

Presented at EAACI Congress 2019 in Lisbon, on 4 June 2019 to the winner, Flore Amat MD, PhD

The awarded research project: Risk Factors For Asthma At School Age In Children With Early-Onset Atopic Dermatitis, was set out to define phenotypes of early-onset AD leading to asthma in a prospective study using an unsupervised statistical approach, using the Observatory of Risks linked with Cutaneous Atopy (ORCA) patients cohort of children aged under 12 months referred for moderate to severe AD. Results showed that,even in this specific population with early-onset AD, not all of the children follow the atopic march. Children with early-multiple sensitization have the highest risk of sensitization to aeroallergens and asthma at school-age. These results from this patients cohort need to be independently validated, and are about to be replicated in two Europeans birth cohorts, MAS and PIAMA.


Brecht Steelant EAACI Allergopharma Award 2018 EAACI Allergopharma Award 2018

Presented at EAACI Congress 2018 in Munich, on 26 May 2018 to the winner, Brecht Steelant PhD, Postdoctoral Researcher

The awarded research project “Regulation Of Epithelial Barrier Function In Allergic Rhinitis”, will be carried out for one year at the Laboratory of Clinical Immunology, in Leuven, Belgium. 
Purpose of the study: Purpose of the study was to unravel the role of epithelial barrier function in allergic rhinitis and how it contributes to disease severity and chronicity. By studying epithelial integrity and tight junction expression, we aim at discovering novel therapeutic approaches in the treatment of allergic rhinitis.


Kristina Britt Charlotte Johansson EAACI Allergopharma Award 2017

Presented at EAACI Congress 2017 in Helsinki, on 17 June 2017 to the winner, Kristina Britt Charlotte Johansson, MSc, PhD candidate

The awarded research project "MicroRNA regulation in asthma", was carried out for one year at Krefting Research Centre at the University of Gothenburg in Gothenburg, Sweden.
Purpose of the study: MicroRNAs regulate cellular pathways and are required for normal cell behavior. By studying microRNA expression under inflammatory settings in humans and mice we aim to uncover novel genes and pathways that are critical to asthma pathology.


Irisz Karolina Levai EAACI Allergopharma Award 2016

Presented at EAACI in Vienna, the 11th of June 2016 to the winner, Irisz Karolina Levai, MD

The awarded research project "Continuous laryngoscopy during exercise and assessment of parasympathetic activity in patients with exercise-induced laryngeal obstruction (EILO)", was carried out for 6 months at Haukeland University Hospital (HUS) in Bergen (Norway).The purpose of this study was to address potential effects from Atrovent in patients with exercise-induced laryngeal obstruction (EILO) verified during a continuous laryngoscopy exercise (CLE) test.


Alexander eggel
EAACI Allergopharma Award 2015

Presented at EAACI in Barcelona, the 7th of June 2015 to the winner, Alexander Eggel, PhD

Dr. Eggel obtained his PhD degree at University of Bern in Switzerland and following a year as Postdoctoral Fellow at the University of Stanford, he returned to Bern and is currently Group Leader at the Institute of Immunology. Over the years, he has received several recognitions for outstanding work in the fields of allergy and immunology.
In several publications the focus of has been on IgE/IgE-receptor interactions. The awarded publication describes the action of a new class of IgE inhibitors with therapeutic potential acting by suppression of the allergic response of effector cells from sensitised individuals.Thereby this paper provides new knowledge as well as points at potential applications in present and future diagnostic and therapeutic regimens.
Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Send feedback